364
Participants
Start Date
January 8, 2014
Primary Completion Date
March 15, 2017
Study Completion Date
May 24, 2023
PF-06463922
Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days
Crizotinib
Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
National Taiwan University Hospital, Taipei
Hospital of Lausanne (CHUV), Lausanne
Chris O'Brien Lifehouse, Sydney
Royal Prince Alfred Hospital, Sydney
Chris O'Brien Lifehouse, Sydney Local Health District [rpa]
University Hospital Antwerp, Edegem
Peter MacCallum Cancer Centre, Melbourne
Royal Melbourne Hospital, Parkville
Kantonsspital Winterthur, Winterthur
National Taiwan University Hospital, Taipei
Rockefeller Patient Pavilion - Memorial Sloan Kettering, New York
Memorial Sloan Kettering Cancer Center, New York
SUNY Upstate Medical University, Syracuse
Rochester Regional Health System, Rochester
Fox Chase Cancer Center, Philadelphia
Georgetown University Medical Center, Washington D.C.
Dipartimento di Oncologia Medica, UO Medicina 1Q A, Unita' Nuovi Farmaci e Terapie Innovative, Milan
Unita di Farmacologia Clinica e Nuovi Farmaci, Milan
Hospital Universitario Quiron Madrid, Pozuelo de Alarcón
Clinica Universidad De Navarra, Pamplona
Institut Universitaire du Cancer de Toulouse (IUCT-O), Toulouse
Struttura Operativa Complessa Oncologia, Aviano (PN)
CHU de Rennes - Hôpital Pontchaillou - CIC Inserm, Rennes
CHU de Rennes - Hôpital Pontchaillou, Rennes
Sarah Cannon Research Institute (Pharmacy), Nashville
Tennessee Oncology PLLC, Nashville
CHU Grenoble/ Hôpital Albert Michallon, Grenoble
The Ohio State University, Columbus
The Ohio State University, Columbus
The Ohio State University, Columbus
Karmanos Cancer Institute, Detroit
Karmanos Center Institute, Detroit
Karmanos Cancer Institute, Farmington Hills
Universitaetsklinik Koeln, Cologne
Barnes-Jewish Hospital, St Louis
Washington University School of Medicine, St Louis
Siteman Cancer Center-South County, St Louis
Siteman Cancer Center-West County, Creve Coeur
Highlands Oncology Group/Research, Fayetteville
Highlands Oncology Group, Rogers
University of Colorado Cancer Center, Aurora
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP), Aurora
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP), Aurora
University of Colorado Hospital - Anschutz Outpatient Pavillion (AOP), Aurora
University of Colorado Hospital, Aurora
Institut Gustave Roussy (comite poumon-pneumologie), Villejuif
Institut Gustave Roussy- Pharmacie-Unite Essais Cliniques, Villejuif
National University Hospital, Singapore
National University Hospital Medical Centre, Singapore
National Cancer Center, Singapore
National Cancer Center, Singapore
Chao Family Comprehensive Cancer Center, Orange
UC Irvine Medical Center, Orange
MDZ: Yale-New Haven Hospital, New Haven
Smilow Cancer Hospital at Yale-New Haven, New Haven
Massachusetts General Hospital, Boston
Brigham and Women's Hospital, Boston
Dana Farber Cancer Institute, Boston
British Columbia Cancer Agency-Vancouver Centre, Vancouver
The Ottawa Hospital Cancer Centre, Ottawa
Princess Margaret Cancer Centre, Toronto
Department of Clinical Oncology, Prince of Wales Hospital, Shatin
Oncologia Medica, Perugia
Aichi Cancer Center Hospital, Nagoya
Nagoya University Hospital, Nagoya
National Cancer Center Hospital East, Kashiwa
National Hospital Organization Shikoku Cancer Center, Matsuyama
Hokkaido University Hospital, Sapporo
Hyogo Cancer Center, Akashi
Kindai University Hospital, Sayama
Shizuoka Cancer Center, Sunto-gun
National Cancer Center Hospital, Chuo-ku
National Hospital Organization Kyushu Cancer Center, Fukuoka
The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo
Seoul National University Hospital / Department of Internal Medicine, Seoul
Hospital Universitario Quiron Dexeus, Barcelona
Hospital Universitari de la Vall D'Hebron Edificio General. Planta Baja. UITM. Servicio de Oncologia, Barcelona
Lead Sponsor
Pfizer
INDUSTRY